We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) reported earnings per share of 4 cents in fourth-quarter 2019, registering a 100% year-over-year surge. The metric also compared favorably with the Zacks Consensus Estimate of a loss of 7 cents.
For full-year 2019, the company posted a loss of 42 cents per share, narrower than the year-ago loss of $2.55 as well as the Zacks Consensus Estimate of loss of 55 cents.
Revenues in the quarter were $108.4 million, beating the Zacks Consensus Estimate by a close margin of 0.6%. The top line surged 42.3% year over year on robust domestic demand for the t:slim X2 insulin pump.
Full-year revenues came in at $362.3 million, indicating a 97% surge from the year-ago period. The revenue figure, however, lagged the Zacks Consensus Estimate by 0.2%.
Q4 Revenues in Detail
Tandem Diabetes registered international sales of $10.2 million during the reported period, marking a 43% jump from fourth-quarter 2018. Domestic sales came in at $98.2 million, up 42% year on year.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
In the fourth quarter, Tandem Diabetes’ worldwide pump shipments soared 113% year over year to 19,602 units. Of these, 2,149 pumps were shipped to international markets, significantly down 34% year over year. Domestic pump shipments, however, jumped 35% year over year to 17,453 units.
Margins
Gross profit in the December-end quarter was $60.3 million, marking 45.1% year-over-year growth. Gross margin was 55.6%, expanding 109 basis points (bps).
Total operating expenses came in at $58.1 million, flaring up 41.9% year over year. Operating margin in the fourth quarter was 1.9%, reflecting a 124-bps expansion year on year.
Financial Position
Tandem Diabetes exited 2019 with cash and cash equivalents of $176.5 million compared with the $129 million recorded at the end of 2018.
Guidance
Tandem Diabetes has issued its 2020 guidance.Sales are projected at $450-$465 million, indicating annual growth of 24-28%. The Zacks Consensus Estimate for the top line is pegged at $441.8 million, which lies below the projected range.
Our Take
Tandem Diabetes delivered better-than-expected results in the fourth quarter. Strength in the t:slim X2 Insulin pump’s domestic sales and the company’s expansion in international markets as well as a robust product pipeline drove the top line significantly during this period. We are impressed with the surge in global pump shipments. The company’s 2020 sales forecast also looks upbeat.
Zacks Rank & Other Stocks to Consider
Currently, Tandem Diabetes flaunts a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks which reported solid results this earnings season are Stryker Corporation (SYK - Free Report) , STERIS plc (STE - Free Report) and ResMed Inc. (RMD - Free Report) .
Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Its quarterly revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
STERIS reported third-quarter fiscal 2020 adjusted EPS of $1.45, beating the Zacks Consensus Estimate by 1.4%. Net revenues of $774.3 million outpaced the consensus estimate by 3.3%. The company carries a Zacks Rank of 2, at present.
ResMed currently carries a Zacks Rank #2. It reported second-quarter fiscal 2020 adjusted EPS of $1.21, surpassing the Zacks Consensus Estimate by 19.8%. Its revenues of $736.2 million outpaced the consensus mark by 1.5%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up
Tandem Diabetes Care, Inc. (TNDM - Free Report) reported earnings per share of 4 cents in fourth-quarter 2019, registering a 100% year-over-year surge. The metric also compared favorably with the Zacks Consensus Estimate of a loss of 7 cents.
For full-year 2019, the company posted a loss of 42 cents per share, narrower than the year-ago loss of $2.55 as well as the Zacks Consensus Estimate of loss of 55 cents.
Revenues in the quarter were $108.4 million, beating the Zacks Consensus Estimate by a close margin of 0.6%. The top line surged 42.3% year over year on robust domestic demand for the t:slim X2 insulin pump.
Full-year revenues came in at $362.3 million, indicating a 97% surge from the year-ago period. The revenue figure, however, lagged the Zacks Consensus Estimate by 0.2%.
Q4 Revenues in Detail
Tandem Diabetes registered international sales of $10.2 million during the reported period, marking a 43% jump from fourth-quarter 2018. Domestic sales came in at $98.2 million, up 42% year on year.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
Tandem Diabetes Care, Inc. price-consensus-eps-surprise-chart | Tandem Diabetes Care, Inc. Quote
In the fourth quarter, Tandem Diabetes’ worldwide pump shipments soared 113% year over year to 19,602 units. Of these, 2,149 pumps were shipped to international markets, significantly down 34% year over year. Domestic pump shipments, however, jumped 35% year over year to 17,453 units.
Margins
Gross profit in the December-end quarter was $60.3 million, marking 45.1% year-over-year growth. Gross margin was 55.6%, expanding 109 basis points (bps).
Total operating expenses came in at $58.1 million, flaring up 41.9% year over year. Operating margin in the fourth quarter was 1.9%, reflecting a 124-bps expansion year on year.
Financial Position
Tandem Diabetes exited 2019 with cash and cash equivalents of $176.5 million compared with the $129 million recorded at the end of 2018.
Guidance
Tandem Diabetes has issued its 2020 guidance.Sales are projected at $450-$465 million, indicating annual growth of 24-28%. The Zacks Consensus Estimate for the top line is pegged at $441.8 million, which lies below the projected range.
Our Take
Tandem Diabetes delivered better-than-expected results in the fourth quarter. Strength in the t:slim X2 Insulin pump’s domestic sales and the company’s expansion in international markets as well as a robust product pipeline drove the top line significantly during this period. We are impressed with the surge in global pump shipments. The company’s 2020 sales forecast also looks upbeat.
Zacks Rank & Other Stocks to Consider
Currently, Tandem Diabetes flaunts a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks which reported solid results this earnings season are Stryker Corporation (SYK - Free Report) , STERIS plc (STE - Free Report) and ResMed Inc. (RMD - Free Report) .
Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Its quarterly revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
STERIS reported third-quarter fiscal 2020 adjusted EPS of $1.45, beating the Zacks Consensus Estimate by 1.4%. Net revenues of $774.3 million outpaced the consensus estimate by 3.3%. The company carries a Zacks Rank of 2, at present.
ResMed currently carries a Zacks Rank #2. It reported second-quarter fiscal 2020 adjusted EPS of $1.21, surpassing the Zacks Consensus Estimate by 19.8%. Its revenues of $736.2 million outpaced the consensus mark by 1.5%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>